Traumatic Brain Injury and Effects of Acute Cyclosporine A
Status:
Withdrawn
Trial end date:
2017-08-07
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, placebo-controlled study about Cyclosporine A (CSP) and
traumatic brain injury (TBI). Cyclosporine A is a drug already marketed and available for
other diseases, but is not approved by the Food and Drug Administration for treatment of
traumatic brain injury. The effect of Cyclosporine A on chemicals produced following brain
injury is being determined using doses no larger than those used for patients having organ
transplant. It is also being given for a much shorter time period (3 days). It is not know if
side effects seen in patients taking cyclosporine A will occur when it is given for only 3
days. It is not known if patients with brain injury that are treated with cyclosporine A will
have side effects like those seen in organ transplant patients.